CTOs on the Move


 
Dermesse is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

LifeCare Health Partners

Improving the lives of people with severe illness or injury takes more than skill and compassion - it takes innovation. A national leader in long term acute care, LifeCare was built on the belief that early and aggressive intervention, coupled with a personalized treatment plan that encompasses body, mind and soul, can maximize a patient`s potential for recovery. Our multi-disciplinary treatment teams are directed by highly-trained, committed physicians and include healthcare professionals involved in all aspects of a patient`s care: nurses, respiratory therapists, physical medicine specialists, radiologists, pharmacists, dietitians and case managers. Our philosophy has impacted the lives of thousands of LifeCare patients, resulting in improved outcomes, shorter hospital stays and more cost-effective treatment. Based in Plano, Texas, the LifeCare Family of Hospitals includes both freestanding and "hospital-in-hospital" acute care hospitals designed to treat medically complex patients who require acute care hospital services for an extended period of time. Currently, our network includes 24 locations in 9 states.

RoslinCT

RoslinCT is a UK-based Cell and Gene Therapy Contract Development and Manufacturing Organisation (CDMO) that provides services for companies developing cell and gene-based therapeutic products. They offer a range of integrated services from GMP transla...

L.B. Bohle

L.B. Bohle, LLC is a Warminster, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bloodworth Wholesale

Bloodworth Wholesale is a Tifton, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Albireo Pharma

Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo`s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo`s clinical pipeline also includes two Phase 2 product candidates. Albireo`s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden.